drugset / Trial / NCT06637007
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
NaSequentialOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |